Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04653246 · ClinicalTrials.gov registry record · Phase 2
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
A Phase 2 study of Multiple Myeloma and Autologous Stem Cell Transplant, sponsored by Jacob Laubach, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT04653246 is a Phase 2 study of Multiple Myeloma and Autologous Stem Cell Transplant that is active but no longer recruiting, run by Jacob Laubach, MD. The registered enrollment target is 52 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04653246, a Phase 2 study of Multiple Myeloma and Autologous Stem Cell Transplant, is active but no longer recruiting, sponsored by Jacob Laubach, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Isatuximab
- DRUG Bortezomib Injection
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2029-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04653246
The ClinicalTrials.gov registry entry for NCT04653246 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The listed sponsor is Jacob Laubach, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT04653246 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04653246 about?
NCT04653246 is a clinical study titled "Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM". This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
What is the current status of trial NCT04653246?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2021-07-13. Estimated completion is 2029-01-13.
What conditions does trial NCT04653246 study?
This clinical trial studies the following conditions: Multiple Myeloma, Autologous Stem Cell Transplant, Newly Diagnosed Multiple Myeloma (NDMM).
What interventions are being tested in trial NCT04653246?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Isatuximab (DRUG), Bortezomib Injection (DRUG).
Who is sponsoring clinical trial NCT04653246?
This trial is sponsored by Jacob Laubach, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04653246 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.